GlobeNewswire Inc.··NaIpsen Launches First-in-Class Neuroinhibitor Corabotase, Targeting Aesthetic and Therapeutic Markets
Ipsen launches corabotase, first-in-class recombinant neuroinhibitor, with positive Phase II data showing rapid onset and sustained effect for glabellar lines, advancing broad clinical program.
IPSEYclinical developmentPhase II trial